Vor Biopharma (VOR) Operating Expenses (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Operating Expenses data on file, last reported at $35.2 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 5.61% year-over-year to $35.2 million in Q1 2026; TTM through Mar 2026 was $373.5 million, a 205.78% increase from a year earlier, with the FY2025 full-year figure at $371.6 million, up 206.67% from the prior year.
• Operating Expenses for Q1 2026 stood at $35.2 million, down from $36.0 million in the prior quarter.
• Over the last five years, Operating Expenses for VOR reached as high as $274.3 million in Q2 2025 and fell as low as $21.8 million in Q2 2022.
• Historically, Operating Expenses has averaged $44.0 million across 5 years, with a median of $30.4 million in 2023.
• Across the five-year window, Operating Expenses declined 19.26% in 2024 and surged 844.67% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $24.7 million in 2022, then rose by 13.75% to $28.1 million in 2023, then increased by 11.33% to $31.3 million in 2024, then increased by 14.85% to $36.0 million in 2025, then dropped by 2.22% to $35.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $35.2 million in Q1 2026, $36.0 million in Q4 2025, and $28.1 million in Q3 2025.